Icosavax to Participate in in Upcoming Investor Conferences

The webcast replays will be available following the conclusion of the presentations for approximately 90 days.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, November 8, 2022

Information

Tags:

GLOBE, Respiratory syncytial virus, Fireside, Vaccine, Severe acute respiratory syndrome coronavirus 2, Fireside chats, RSV, University of Washington Department of Global Health, Human, Technology, Investor relations, Institute, Infection, Virus, VLP, ET, University

Geotags:

SEATTLE, WA, US

⚠ partially generated by AI ↴

Organisation:

ICOSAVAX, ICOSAVAX, INC.

Summary

Key Points:

The webcast replays will be available following the conclusion of the presentations for approximately 90 days.
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines.
Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
Icosavax is located in Seattle.

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences:

Guggenheim 4th Annual Immunology and Neurology Conference

Icosavax will present on Tuesday, November 15 at 9:00 am ET

Jefferies London Healthcare Conference

Icosavax will participate in a Fireside Chat on Thursday, November 17 at 6:20 am ET

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com. The webcast replays will be available following the conclusion of the presentations for approximately 90 days.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as programs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

For more information, visit www.icosavax.com.

Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
[email protected]
858.344.8091

Investor Contact:
Laurence Watts
Gilmartin Group, LLC
[email protected]
619.916.7620